Latest Breaking News On - Proposed eylea - Page 1 : comparemela.com

On May 17, 2024, Regeneron filed a second infringement litigation against Celltrion's proposed EYLEA® (aflibercept) biosimilar CT-P42, Case No. 1:24-cv-00053 (N.D.W. Va.).

Mylan yesafiliBiocon biologicsApril breyer menonSamsung bioepis opuvizRegeneron complaintProposed eyleaSamsung bioepisFirst two interchangeableFinal written decisions